(Q39246432)

10 September 2017

title

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines (English)

1 reference

ORCID Public Data File 2021

10 September 2017

1 reference

1 reference

author name string

Brigette B Y Ma

1

1 reference

10 September 2017

Vivian W Y Lui

2

1 reference

10 September 2017

Connie W C Hui

3

1 reference

10 September 2017

Cecilia P Y Lau

4

1 reference

10 September 2017

Chi-Hang Wong

5

1 reference

10 September 2017

Edwin P Hui

6

1 reference

10 September 2017

Margaret H Ng

7

1 reference

10 September 2017

S W Tsao

8

1 reference

10 September 2017

Yan Li

9

1 reference

10 September 2017

Anthony T C Chan

10

1 reference

10 September 2017

publication date

11 November 2012

1 reference

Investigational New Drugs

10 September 2017

published in

1 reference

10 September 2017

volume

31

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

567-575

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-012-9896-5

10 September 2017

exact match

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

PIK3CA mutations in nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

LMP1 strain variants: biological and molecular properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9896-5

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.

21 January 2018

1 reference

12 December 2020

Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma

1 reference

12 December 2020

[Expression and significance of PTEN in nasopharyngeal carcinoma]

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization

1 reference

12 December 2020

Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines

1 reference

12 December 2020

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

1 reference

12 December 2020

10.1007/S10637-012-9896-5

Identifiers

DOI

1 reference

10 September 2017

1 reference